Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Humacyte Q3 2026 Results: Net Loss of $15.5M, Loss Narrows

Humacyte, Inc. reported a significant increase in cash and cash equivalents to $64.5 million as of September 30, 2026, following the commercialization of Symvess. The company recorded a litigation settlement liability of $9.75 million and an accumulated deficit of $796.8 million, while common stock outstanding grew to over 277 million shares.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1.00.8
Net income-15.5-17.5
EPS (diluted, $ a share)$-0.06$-0.11

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+36.5%
Source

10-Q filed with the SEC, NASDAQ: HUMA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Humacyte, Inc.: key numbers

Share price
$0.5403Close, Nov 16
Market cap
$150M
Shares outstanding
277.8MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Humacyte, Inc.

All →
7:05 AM ET 8-K
Financial Results

Humacyte Financial Results

Humacyte reported Q3 2026 financial results, highlighted by a 151% sequential increase in Symvess revenue to $1.0 million. The company remains on track to file a supplemental Biologics License Application (sBLA) for its ATEV in dialysis access with the FDA in November 2026.

Term
Q3 2026

“During our third quarter, we continued the transformation of our Symvess commercial program in vascular injury repair, doubling revenue over our second quarter and significantly increasing the number of hospitals ordering Symvess.”

Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte

“Execution of our revamped commercial program for Symvess generated significant momentum during the third quarter. Symvess sales revenue for the third quarter was $1.0 million, more than double our results for the second quarter, and achieved the goal we set for the period.”

Jim Mercadante, Chief Commercial Officer of Humacyte
4:06 PM ET 8-K
Leadership Change

Humacyte Leadership Change

Humacyte, Inc. appointed life science industry veterans Scott Coward and Paul Kuznik to its Board of Directors, effective September 22, 2026. Coward, a former executive at Exact Sciences, and Kuznik, a former CEO of Bolton Medical, bring extensive experience in commercialization and global operations as the company prepares for the planned launch of its ATEV product in dialysis access.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.